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Abstract 
Background: Intensive care units (ICUs) in lower-middle income countries (LMICs) are suspected to constitute a 
special risk for patients of acquiring infection due to multiple antibiotic resistant organisms. The aim of this system-
atic scoping review was to present the data published on ICU-acquired infections and on antimicrobial resistance 
observed in ICUs in LMICs over a 13-year period. A systematic scoping review was conducted according to the 
PRISMA extension guideline for scoping reviews and registered in the Open Science Framework.
Main body of the abstract: Articles were sought that reported on ICU-acquired infection in LMICs between 2005 
and 2018. Two reviewers parallelly reviewed 1961 titles and abstracts retrieved from five data banks, found 274 eligible 
and finally included 51. Most LMICs had not produced reports in Q1 or Q2 journals in this period, constituting a 
large gap in knowledge. However, from the reported evidence it is clear that the rate of ICU-acquired infections was 
comparable, albeit approximately 10% higher, in LMICs compared to high income countries. In contrast, ICU mortality 
was much higher in LMICs (33.6%) than in high income countries (< 20%). Multidrug-resistant Gram-negative species, 
especially Acinetobacter baumannii and Pseudomonas aeruginosa, and Klebsiella pneumoniae played a much more 
dominant role in LMIC ICUs than in those in high income countries. However, interventions to improve this situation 
have been shown to be feasible and effective, even cost-effective.
Conclusions: Compared to high income countries the burden of ICU-acquired infection is higher in LMICs, as is the 
level of antimicrobial resistance; the pathogen distribution is also different. However, there is evidence that interven-
tions are feasible and may be quite effective in these settings.
Protocol Registration The protocol was registered with Open Science Framework (https ://osf.io/c8vjk )
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Introduction
Approximately fifty countries of the world belong to the 
category of lower-middle income countries (LMICs) 
according to the long-standing classification by the 
World Bank and updated every year [1]. These LMICs 
share the same bracket of Gross National Income (GNI) 
per capita—$1026 and $3955 (2019)—a proxy for the 
level of their economic progress. This LMIC group is 
a quite diverse group by region, size, population, and 
income level, ranging from tiny nations with small popu-
lations to giants like India and Indonesia (Fig. 1).
LMICs are known to be already affected by the 
worldwide pandemic of antimicrobial resistance. In 
the future, LMICs are considered to be at high risk 
of additional morbidity and mortality due to patho-
gens resistant to multiple antimicrobial agents as was 
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stated in the report from the Wellcome Trust in 2014 
[2]. Patients admitted to intensive care units (ICUs) are 
particularly at risk of acquiring infection due to multi-
ple antibiotic resistant strains of notorious nosocomial 
pathogens including Enterococcus spp., Staphylococ-
cus aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa and Escherichia coli 
(a.k.a. the ESKAPE group of pathogens) [3]. A large 
international point prevalence survey on infections in 
the ICU conducted on May  8th, 2007 included 1265 
ICUs in 75 countries and provided insight in the preva-
lence and outcomes of such infections [4]. However, 
only eight LMICs participated in that survey and data 
on the occurrence and determinants of ICU-acquired 
infections and antimicrobial resistant pathogens from 
LMICs remain relatively rare and published wide 
apart. We, therefore, present here a scoping review of 
the data published on the infections and antimicrobial 
resistance observed in ICUs in LMICs over a 13-year 
period and published in esteemed scientific journals. 
We focused on revealing which LMICs have produced 
relevant information in this period, and which not, 
what type of ICU infections were observed and at what 
frequencies, which species and types caused these 
ICU-acquired infections, and present their antibiotic 
resistance profile. In addition, information was sought 
about the role of healthcare workers (HCWs) and the 
ICU environment, and whether intervention studies 
were performed and, if so, successful in reducing (risk 
of ) infections in these settings.
Methods
Protocol and registration
The scoping review protocol was developed as recently 
recommended by PRISMA extension for scoping reviews 
[5–7] and registered with Open Science Framework, an 
international prospective register of systematic scoping 
reviews on 13th December 2019 (https ://osf.io/c8vjk ) [5, 
6].
Eligibility criteria
Any study that targeted the etiology and management of 
nosocomial bacterial infections in adult ICUs in LMICs, 
with a focus on antimicrobial resistance and interven-
tions applied were eligible. Also, results of screening for 
multidrug-resistant bacterial pathogens (ESKAPE spe-
cies) among humans (patients and HCWs) and the hos-
pital environment were considered eligible for inclusion 
in this review.
The population, intervention, comparison, and out-
come (PICO) framework for determining the eligibility of 
the studies for the primary research question is presented 
in Table 1.
Information sources and search
We conducted a systematic scoping review of the epide-
miology and management of multidrug-resistant bacte-
ria in adult ICUs in countries classified as lower-middle 
Fig. 1 Global Map highlighting lower-middle income countries (blue)
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income countries (LMICs) according to the World Bank 
(WB) in 2015. As stated by the WB, for the 2015 fiscal 
year, lower-middle income economies were those with 
a GNI per capita between $1026 and $4035. Thus, low 
income countries were not included in this review. The 
term country refers to any territory for which authorities 
report separate social or economic statistics.
The scoping review protocol was developed and regis-
tered in the Open Science Framework, an international 
prospective register of systematic scoping reviews, as 
recently recommended by PRISMA extension for scop-
ing reviews [5, 6]. A systematic scoping review is a type of 
evidence synthesis method aimed at mapping the range 
of literature that exists around a specific topic of interest 
and focuses the research questions by charting the exist-
ing research findings and identifying research gaps. Scop-
ing methodology is also considered a useful approach for 
determining the need and value of a future primary (in-
depth study) or a full systematic review [5].
The review is restricted to papers published from Janu-
ary 1st 2005 until January 1st 2018, a time frame that is 
wide enough to allow all LMICs to contribute relevant 
data, and recent enough to still be relevant for today. We 
used EMBASE as the starting point and subsequently 
serially queried OvidSP ‘Medline’, Cochrane, Web of 
Science and finally Google Scholar. The relevant litera-
tures were identified using a single-line search strategy 
[8] with the following search strings:
Embase.com
(’intensive care unit’/exp OR (((’intensive care’ OR ’criti-
cal care’) NEXT/1 unit*) OR icu OR icus):ab,ti) AND 
(infection/exp OR ’antibiotic resistance’/exp OR ’infec-
tion prevention’/exp OR ’infection control’/exp OR 
’vancomycin resistant Enterococcus’/de OR ’methicil-
lin resistant Staphylococcus aureus’/de OR ’extended 
spectrum beta lactamase’/de OR ’carbapenemase’/de 
OR ’Pseudomonas aeruginosa’/exp OR ’Acinetobacter 
baumannii’/exp OR (infection* OR sepsis OR septic OR 
nosocomial* OR mrsa OR ((multidrug OR multi-drug 
OR resistan*) NEAR/3 (bacter*)) OR ((vancomycin OR 
methicillin OR carbapenem) NEAR/3 resistan*) OR vre 
OR mrsa OR esbl OR (antibiotic* NEAR/3 resistan*) OR 
’extended spectrum beta lactamase’ OR ’extended spec-
trum β lactamase’ OR ’Pseudomonas aeruginosa’ OR 
’Acinetobacter baumannii’):ab,ti) AND (((’lower middle’ 
OR ’low middle’ OR ’low- and middle’) NEAR/6 income 
NEAR/3 countr*) OR lmic OR lmics OR Armenia* OR 
Mongolia* OR Bhutan* OR Morocc* OR Bolivia* OR 
Nicaragua* OR (Cabo NEXT/1 Verde*) OR Nigeria* OR 
Table 1 Inclusion and exclusion criteria for this scoping review
Criteria Inclusion Exclusion
Population Human Animal, plants
Adult Children and neonates
Intensive care units Other hospital wards
ICU infections, especially those acquired during ICU stay
Laboratory results of screening for the presence of multidrug-resistant bacteria, espe-
cially ESKAPE species among ICU patients, healthcare workers, or the ICU environment
Lower-middle income countries
Intervention Preventive measures to limit nosocomial acquisition and infection of bacterial patho-
gens
Comparator Not Applicable
Outcomes Infection and/or acquisition
Identification and susceptibility pattern of targeted pathogens (ESKAPE species)




Study design Case control study Editorials
Cohort studies Case series reports




Quality of journal Q1 or Q2 based on rank on Web of Science Q3 or Q4, or not ranked in Web of Science
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Cameroon* OR Pakistan* OR Congo* OR (’Papua New’ 
NEXT/1 Guinea*) OR ’Cote d Ivoire’ OR Paraguay* OR 
Djibout* OR Philippin* OR Egypt* OR Samoa* OR Sal-
vador* OR ’Sao Tome and Principe’ OR Georgia* OR 
Senegal* OR Ghan* OR ’Solomon Islands’ OR Guate-
mal* OR Guyana* OR (Sri NEXT/1 Lank*) OR Hondur* 
OR Sudan* OR India OR Swaziland* OR Indonesia* OR 
Syria* OR Kiribati* OR ’Timor-Leste’ OR Kosov* OR 
Ukrain* OR Kyrgyz* OR Uzbek* OR Lao OR laos OR 
Vanuatu* OR Lesotho* OR Vietnam* OR Mauritania* OR 
(’West Bank’ NEXT/2 Gaza) OR Micronesia* OR Yemen* 
OR Moldova* OR Zambia*):de,ab,ti NOT (((child/exp OR 
pediatrics/exp) NOT adult/exp) OR (pediatric* OR picu 
OR nicu OR picus OR nicus):ab,ti).
Medline (OvidSP)
(Intensive Care Units/ OR (((intensive care OR critical 
care) ADJ unit*) OR icu OR icus).ab,ti.) AND (exp infec-
tion/ OR exp Drug Resistance, Microbial/ OR Vanco-
mycin-Resistant Enterococci/ OR Methicillin-Resistant 
Staphylococcus aureus/ OR Pseudomonas aeruginosa/ 
OR Acinetobacter baumannii/ OR (infection* OR sepsis 
OR septic OR nosocomial* OR mrsa OR ((multidrug OR 
multi-drug OR resistan*) ADJ3 (bacter*)) OR ((vanco-
mycin OR methicillin OR carbapenem) ADJ3 resistan*) 
OR vre OR mrsa OR esbl OR (antibiotic* ADJ3 resistan*) 
OR extended spectrum beta lactamase OR Pseudomonas 
aeruginosa OR Acinetobacter baumannii).ab,ti.) AND 
(((lower middle OR low middle OR low- and middle) 
ADJ6 income ADJ3 countr*) OR lmic OR lmics OR 
Armenia* OR Mongolia* OR Bhutan* OR Morocc* OR 
Bolivia* OR Nicaragua* OR (Cabo ADJ Verde*) OR Nige-
ria* OR Cameroon* OR Pakistan* OR Congo* OR (Papua 
New ADJ Guinea*) OR Cote d Ivoire OR Paraguay* OR 
Djibout* OR Philippin* OR Egypt* OR Samoa* OR Sal-
vador* OR Sao Tome and Principe OR Georgia* OR Sen-
egal* OR Ghan* OR Solomon Islands OR Guatemal* OR 
Guyana* OR (Sri ADJ Lank*) OR Hondur* OR Sudan* 
OR India OR Swaziland* OR Indonesia* OR Syria* OR 
Kiribati* OR Timor-Leste OR Kosov* OR Ukrain* OR 
Kyrgyz* OR Uzbek* OR Lao OR laos OR Vanuatu* OR 
Lesotho* OR Vietnam* OR Mauritania* OR (West Bank 
ADJ2 Gaza) OR Micronesia* OR Yemen* OR Moldova* 
OR Zambia*).kw,ab,ti. NOT (((exp child/ OR exp pediat-
rics/) NOT exp adult/) OR (pediatric* OR picu OR nicu 
OR picus OR nicus).ab,ti.)
Cochrane
((((’intensive care’ OR ’critical care’) NEXT/1 unit*) OR 
icu OR icus):ab,ti) AND ((infection* OR sepsis OR sep-
tic OR nosocomial* OR mrsa OR ((multidrug OR multi-
drug OR resistan*) NEAR/3 (bacter*)) OR ((vancomycin 
OR methicillin OR carbapenem) NEAR/3 resistan*) OR 
vre OR mrsa OR esbl OR (antibiotic* NEAR/3 resistan*) 
OR ’extended spectrum beta lactamase’ OR ’extended 
spectrum β lactamase’ OR ’Pseudomonas aeruginosa’ OR 
’Acinetobacter baumannii’):ab,ti) AND (((’lower middle’ 
OR ’low middle’ OR ’low- and middle’) NEAR/6 income 
NEAR/3 countr*) OR lmic OR lmics OR Armenia* OR 
Mongolia* OR Bhutan* OR Morocc* OR Bolivia* OR 
Nicaragua* OR (Cabo NEXT/1 Verde*) OR Nigeria* OR 
Cameroon* OR Pakistan* OR Congo* OR (’Papua New’ 
NEXT/1 Guinea*) OR ’Cote d Ivoire’ OR Paraguay* OR 
Djibout* OR Philippin* OR Egypt* OR Samoa* OR Sal-
vador* OR ’Sao Tome and Principe’ OR Georgia* OR 
Senegal* OR Ghan* OR ’Solomon Islands’ OR Guate-
mal* OR Guyana* OR (Sri NEXT/1 Lank*) OR Hondur* 
OR Sudan* OR India OR Swaziland* OR Indonesia* OR 
Syria* OR Kiribati* OR ’Timor-Leste’ OR Kosov* OR 
Ukrain* OR Kyrgyz* OR Uzbek* OR Lao OR laos OR 
Vanuatu* OR Lesotho* OR Vietnam* OR Mauritania* OR 
(’West Bank’ NEXT/2 Gaza) OR Micronesia* OR Yemen* 
OR Moldova* OR Zambia*):ab,ti NOT ((pediatric* OR 
picu OR nicu OR picus OR nicus):ab,ti).
Web‑of‑science
TS = ((((("intensive care" OR "critical care") NEAR/1 
unit*) OR icu OR icus)) AND ((infection* OR sepsis OR 
septic OR nosocomial* OR mrsa OR ((multidrug OR 
multi-drug OR resistan*) NEAR/3 (bacter*)) OR ((van-
comycin OR methicillin OR carbapenem) NEAR/3 
resistan*) OR vre OR mrsa OR esbl OR (antibiotic* 
NEAR/3 resistan*) OR "extended spectrum beta lacta-
mase" OR "extended spectrum β lactamase" OR "Pseu-
domonas aeruginosa" OR "Acinetobacter baumannii")) 
AND ((("lower middle" OR "low middle" OR "low- and 
middle") NEAR/6 income NEAR/3 countr*) OR lmic 
OR lmics OR Armenia* OR Mongolia* OR Bhutan* OR 
Morocc* OR Bolivia* OR Nicaragua* OR (Cabo NEAR/1 
Verde*) OR Nigeria* OR Cameroon* OR Pakistan* OR 
Congo* OR ("Papua New" NEAR/1 Guinea*) OR "Cote 
d Ivoire" OR Paraguay* OR Djibout* OR Philippin* 
OR Egypt* OR Samoa* OR Salvador* OR "Sao Tome 
and Principe" OR Georgia* OR Senegal* OR Ghan* OR 
"Solomon Islands" OR Guatemal* OR Guyana* OR (Sri 
NEAR/1 Lank*) OR Hondur* OR Sudan* OR India OR 
Swaziland* OR Indonesia* OR Syria* OR Kiribati* OR 
"Timor-Leste" OR Kosov* OR Ukrain* OR Kyrgyz* OR 
Uzbek* OR Lao OR laos OR Vanuatu* OR Lesotho* OR 
Vietnam* OR Mauritania* OR ("West Bank" NEAR/2 
Gaza) OR Micronesia* OR Yemen* OR Moldova* OR 
Zambia*) NOT ((pediatric* OR picu OR nicu OR picus 
OR nicus))).







The references resulting from the Google Scholar data 
bank search were subsequently sorted by relevance, and 
only the first 200 references downloaded for inclusion [8].
Study eligibility
We followed the outlined stages of study selection guided 
by the aforementioned eligibility criteria (Fig.  2). After 
retrieving by an experienced librarian, eligible papers 
(titles and abstracts) were exported to EndNote Library. 
The first author (YRS) screened all titles and abstracts 
and selected papers based on inclusion criteria. Another 
reviewer (HAV) independently performed a parallel 
review of titles and abstracts, and discrepancies between 
the two reviewers were resolved through consensus.
Subsequently, eligible papers published in journals 
ranked by their impact score as Q1 or Q2 in the Web of 
Science were selected for inclusion in the primary analy-
sis. Full texts of the papers so selected were retrieved for 
full text review in a third round of screening for inclu-
sion based on the criteria stated above, with reason for 
exclusion noted for each paper excluded on the basis of 
this full text review.
Papers excluded from the primary analysis based on 
the ranking of their journal of publication and those 
excluded during full text analysis were saved in sepa-
rate files for potential analysis of specific questions aris-
ing during the remainder of the review process. Custom 
groups in EndNote were used to distinguish between 
various reasons for exclusion (Table 1), and articles were 
assigned to specific groups for certain sub-questions. 
The reviewers (YRS and HAV) worked in their own cop-
ies of this library. After reading all articles, each refer-
ence in the library was discussed in detail; therefore, no 
automatic comparison was used and any discrepancy was 
resolved [7].
Data extraction
Data were extracted by first author (YRS) and inputted 
into a data extraction table (Excel) and independently 
checked by the senior author (HAV) to ensure quality.
The extracted data comprised the characteristics of 
each study (first author name, year of publication, coun-
try, study period and design), characteristics of hospital 
and adult ICUs, population characteristics, the type and 
characteristics of adult ICU-associated infection, labo-
ratory diagnosis, the total and individual number of the 
species (Gram-negative and Gram-positive) isolated from 
Fig. 2 Overview of study methodology
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patients, HCW screening and environmental screening, 
their phenotypic and genotypic resistance characteristic, 
and the outcomes of patients (see Table 1).
Collecting and summarizing the findings
Thematic analysis was performed to identify the current 
etiology and management of nosocomial bacterial infec-
tions in adult ICUs in LMICs from the included studies. 
Where possible the results from the LMICs were com-
pared with similar data collected from West-European 
countries in the same time frame. [4, 9–11].
Results
Study selection
After duplicates were removed, a total of 1961 citations 
were identified from searches of electronic databases 
(Fig.  3). Based on the title and the abstract, 1687 were 
excluded, with 274 eligible articles published in journals 
ranked by their impact score by the Web of Science. Of 
these 274 articles, 93 were published in Q1 or Q2 jour-
nals and these 93 articles were subjected to a third round 
of eligibility check. Forty-two were excluded for speci-
fied reasons (see Fig. 3 for reasons of exclusion) and the 
remaining 51 papers were included in the primary analy-
sis of this scoping review.
Geographical distribution and characteristics of included 
studies
All included studies were carried out in LMICs and were 
published between 2005 and 2018. Fifty-one qualified 
studies were conducted in South Asia (India: 22 stud-
ies [12–33], Pakistan: 2 [34, 35]), Middle East & North 
Africa (Egypt: 9 [36–44], Morocco: 2 [45, 46]), East Asia 
& Pacific (Vietnam: 6 [47–52], Indonesia: 2 [53, 54], Phil-
ippines: 2 [55, 56], Mongolia: 1 [57]), Sub-Saharan Africa 
(Nigeria: 2 [58, 59], Ghana: 1 [60]), and Europe & Central 
Asia (Kosovo: 2 [61, 62]) (Fig. 4). Thus, the large major-
ity of LMIC did not have information on ICU-associated 
infections published in Q1 or Q2 journals in this time 
frame. Most publications described surveillance and 
observational studies, only ten publications reported on 
intervention studies, either randomized or quasi-experi-
mental in design. Multicenter studies were described in 
28 publications.
The characteristics of ICUs were not uniform, because 
some ICUs were highly specialized wards, including Burn 
Fig. 3 Flowchart for literature search
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ICU’s or Liver and post-transplant ICUs. However, most 
were mixed medical-surgical units with an open ward 
design. The number of beds per ICU ranged between 4 
and 75 with a median (interquartile range [IQR]) size of 
10 (8–15). The majority of patients were male (38–79%). 
Eleven studies presented the median of age of patients 
admitted, it ranged from 25 to 61 years, with a mean of 
the medians of 53 years. Twenty-three studies presented 
the mean age of patients admitted, it ranged from 32 to 
71  years, with a mean of the means of 50  years. In the 
contemporary EPIC II study, the mean age of patients 
admitted to ICUs was 60.7 years [9].
ICU infection rate and outcomes
The overall frequency of ICU infections was presented 
using three types of calculations, as an attack rate in 11 
>10 studies
 5 -10 studies
1- 5 studies
other LMIC, 0 studies
Fig. 4 LMICs highlighted by number of studies reporting on Intensive Care Unit-associated infections in 2005–2018
















Attack rate 22,403 2032 9.1/100 admissions [13, 15, 28, 36, 45, 49, 
50, 58, 59, 61, 62]
Point prevalence 2129 476 22.4/100 admitted [13, 28, 42–44, 53, 
58, 62]
Incidence rate 3614 397,307 9.1/1000 ICU days [13, 15, 28, 41, 43, 
44, 59]
VAP rate 1404 VAP 124,393 days on 
ventilator
11.3/1000 days on 
ventilator
[14–16, 22, 25, 26, 28, 
32, 38, 39, 41, 44, 
48, 57]
CLABSI rate 1053 CLABSI 255,828 days with 
central line
4.1/1000 days with 
central line
[14–16, 21, 25, 28, 32, 
33, 38, 39, 41, 44, 
55, 57]
CAUTI rate 916 CAUTI 300,679 days with 
catheter
3.0/1000 days with 
catheter
[14–16, 25, 28, 32, 
37–39, 41, 44, 48, 
55–57]
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reports, as point prevalence in eight and as incidence 
rate in seven, with some reports using multiple measures 
(Table  2). The overall attack rate was 9.1 infections/100 
admissions, and varied between 4.4 and 129.3/100 admis-
sions [13, 15, 28, 36, 45, 49, 50, 58, 59, 61, 62]. We iden-
tified point prevalence data in 8 studies, overall it was 
22.4 infected patients/100 admitted patients, and varied 
between 8.5 and 50 [13, 28, 42, 43, 53, 58, 59, 62]. The 
overall incidence rate was 9.1 infections/1000 patients 
days, based on data from 7 studies, it varied between 
2.4 and 79 infections/1000 patients days in the ICU [13, 
15, 28, 41, 43, 44, 59]. Expressed as device specific inci-
dences ventilator-associated pneumonia (VAP) occurred 
at a rate of 11.3 episodes/1000 days on ventilation, central 
line-associated blood stream infection (CLABSI) at 4.1 
episodes/1000 days with central line and catheter-associ-
ated urinary tract infection (CAUTI) at a rate of 3.0 epi-
sodes/1000 days with urinary catheter (Table 2).
The median lengths of stay were presented in 15 studies 
[13, 28, 30–32, 38, 47, 48, 50, 52, 54, 58–60, 62], it ranged 
between 5 and 17 days. We calculated an overall median 
of the medians length of stay of 11 days, and an overall 
mean of the medians length of stay of 10 days. The over-
all in-ICU mortality rate extracted from 18 studies was 
33.6% (1753/5241) patients. If we looked at individual 
studies, we found a wide range in recorded mortality 
rates varying between 14 and 70% [13, 17, 20, 25, 30–33, 
37, 41, 46, 52, 54, 59, 60].
Etiology of infection acquired in ICU
Information on pathogens causing all ICU-associated 
infections was available from 11 studies [13, 16, 28, 32, 
36, 43, 47, 50, 52, 58, 61], six studies included microbio-
logical data specifically related to VAP [13, 14, 26, 28, 58, 
59], seven had data related to CAUTI [13, 14, 28, 37, 56, 
58, 59] and six had CLABSI data [13, 14, 21, 28, 58, 59].
Gram-negative bacilli constituted the most preva-
lent group of nosocomial pathogens in these ICUs. The 
most common single pathogens causing ICU-acquired 
infection in LMICs were A. baumannii (24%), P. aer-
uginosa (16%), K. pneumoniae (15%), these caused the 
majority of infections. This distribution of pathogens 
is significantly different from the distribution of patho-
gens causing ICU-acquired infection in West-European 
countries in the same period, where these same three 
species caused < 25% of all infections [9]. In the Euro-
pean setting, Gram-positive pathogens were more 
Fig. 5 Distribution of ESKAPE pathogens causing ICU-acquired infection in LMICs and in West European countries. ESKAPE pathogens include 
Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli. Data from 
West European countries were extracted from reference [9]
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prominent and the group of other nosocomial agents of 
ICU infection was larger (Fig. 5).
A. baumannii was the most frequent pathogen iden-
tified for ventilator-associated pneumonia causing 42% 
of VAP, followed by P. aeruginosa which caused 25% 
of the VAP. Thus, these two species were involved in 
two thirds of all episodes of VAP in LMICs (Fig. 6). In 
contrast, K. pneumoniae was the dominant species in 
CLABSI, causing 24% of the episodes, as much as the 
combined impact of A. baumannii and P. aeruginosa. 
Together, the ESKAPE species were involved in two 
thirds of all CLABSI episodes. ESKAPE species also 
caused 51% of CAUTI in this setting, with E. coli as 
the most prevalent representative species. However, a 
sizable minority of CAUTI were caused by other spe-
cies of uro-pathogenic microorganisms including many 
episodes that were caused by Candida species (data not 
shown).
Phenotypic susceptibility pattern
Phenotypic resistance profiles of ESKAPE isolates to vari-
ous antibiotics was determined in 15 studies. However, 
these studies were reported from only six LMICs, and 
were sometimes lacking data on certain combinations 
of ESKAPE species and classes of antimicrobial agents. 
Almost all isolates from LMICs were resistant to multiple 
classes of antibiotics, a condition that closely resembles 
the resistance patterns observed in most so-called Medi-
terranean countries, including Italy and Greece, located 
in the southern part of West-Europe (Table 3). Compared 
to isolates from LMICs, the same species isolated from 
invasive infections in Nordic countries of West-Europe, 
including Sweden and the Netherlands, displayed much 
lower levels of antibiotic resistances (Table 3). Vancomy-
cin resistance among Enterococcus species was > 50% in 
Vietnam [50] and MRSA (methicillin-resistant Staphy-
lococcus aureus) was identified in > 50% of all S. aureus 
isolates in most LMICs [28, 30, 35, 50, 59]. Multidrug 
resistant K. pneumoniae, A. baumannii, and P. aerugi-
nosa were found among > 50% of the isolates in India, 
Pakistan, Egypt, Vietnam and Nigeria [13, 20, 27, 28, 35, 
40, 42, 47, 52].
Genotypic resistance pattern
Only a very few studies presented genetic information 
regarding the antibiotic resistances observed. Amis-
sah et  al. from Ghana reported that 28% of  isolates 
of S. aureus tested positive for the mecA gene [60]. 
Fig. 6 Distribution of ESKAPE pathogens causing Ventilator-Associated Pneumonia (VAP), Catheter-Associated Urinary Tract Infection (CAUTI) 
and Central Line-Associated Bloodstream Infection (CLABSI) in ICUs in lower-middle income countries, 2005–2018. ESKAPE pathogens include 
Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli 
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Carbapenemase genes (blaOXA-23, blaOXA-51, blaOXA-66, 
blaOXA-68) in A. baumannii were characterized in four 
studies, in Indonesia [54], Egypt [40, 42] and Morocco 
[46].
Environment screening
Environmental screening cultures were performed and 
reported in four separate studies only. Taneja et  al. in 
2005 in India [12] collected 178 environmental samples 
from various sources and fluids in their main and trans-
plant ICUs and found 51 (28.7%) to be contaminated 
with potential pathogens, of which 31 (17.4%) were con-
taminated with Gram-positive bacteria, 26 (14.6%) with 
Gram-negative bacilli and 11 (6.2%) with fungi.
Gupta et al. [27] more recently reported the presence 
of A. baumannii in 17/26 (65%) samples of humidifier 
water, and in 3/6 (50%) heat and moisture exchangers 
cultured in their ICU in a tertiary care center in South 
India. These environmental isolates showed the same 
multidrug resistance pattern as contemporary isolates 
from patients admitted to the ICU.
In Morocco, Uwingabiye et  al. [46] identified 36 
environmental A. baumannii isolates and compared 
them with 47 clinical isolates of the same species. They 
showed genetic similarity between the clinical and envi-
ronmental isolates since 80/83 (96.4%) of all isolates 
belonged to the same 7 pulsed-field gel electrophore-
sis pulsotypes. Saharman et  al. [54] likewise found six 
isolates of carbapenem-non-susceptible A. baumannii-
calcoaceticus complex in the environment of two ICUs 
in a tertiary care center Indonesia, four of these isolates 
belonged to same dominant clone, defined by multilo-
cus sequence typing, as those infecting their patients.
Table 3 Phenotypic susceptibility patterns of  ESKAPE species causing ICU infection in  lower-middle income countries 




















Enterococcus spp. Vancomycin 
S. aureus Methicillin 
K. pneumoniae Aminoglycoside 
K. pneumoniae Fluoroquinolone 
K. pneumoniae 3rd gen. 
cephalosporins 
K. pneumoniae Carbapenems 
A. baumannii Aminoglycosides 
A. baumannii Fluoroquinolones 
A. baumannii Carbapenems 
P. aeruginosa Aminoglycosides 
P. aeruginosa Ceftazidime 
P. aeruginosa Piperacillin/tazo 
P. aeruginosa Fluoroquinolones 
P. aeruginosa Carbapenems 
E. coli Aminoglycosides 
E. coli Fluoroquinolones 
E. coli 3rd gen. 
cephalosporins 
E. coli Carbapenems 
Level of resistance:  Data from indicated European Union countries were derived from reference [11]. Colors indicate increasing levels of resistance as specified in the 
legend, and blank boxes indicate that no data was available for the particular combination of species and antimicrobial agent
Page 11 of 19Saharman et al. Antimicrob Resist Infect Control           (2021) 10:22  
Healthcare worker screening
HCWs may be another source of nosocomial patho-
gens, thus HCW screening may be an important 
measure to detect and eradicate such sources of antimi-
crobial resistance. However, only two studies address-
ing HCW carriage of resistant pathogens were available 
from LMICs in this time frame, one from Indonesia 
[54] and one from Ghana [60].
Saharman et  al. [54] identified one HCW in their 
ICUs that carried a strain of carbapenem-non-suscep-
tible A. baumannii-calcoaceticus complex, and Amis-
sah et al. [60] found colonization with S. aureus isolates 
that were obtained from 13/29 (45%) of their HCWs, 
but only one of which carried MRSA.
Intervention study
We identified 10 publications that described inter-
ventions aimed to reduce ICU-acquired infections 
and antimicrobial resistances; all but one applied a 
quasi-experimental design to measure the effects of 
their intervention (Table  4) [18, 21–24, 33, 34, 48, 49, 
56]. Multimodal strategies (those with ≥ 3 compo-
nents implemented in an integrated manner to achieve 
improved outcomes and change behavior as defined by 
WHO guidelines) were used in most studies [63]. Out-
comes were either processes, especially hand hygiene 
(HH) practice, in five studies or they were actual rates 
of ICU-acquired infections in seven studies (two studies 
had both types of outcomes, Table  4). Thu et  al. (2015) 
in Vietnam performed a cost-effectiveness study analyz-
ing the impact of a HH improvement program in ICUs. 
The study used the steps recommended by the WHO, 
including upgrading HH facilities, training, surveillance, 
and feedback. The study showed that HH compliance 
increased from 25.7 to 57.5% and the incidence of HAI 
decreased from 31.7 to 20.3% (p < 0.001) after the inter-
vention; similar results were shown in several reports 
from India [18, 23, 24].
Successful interventions have also targeted CLABSI, 
VAP, and CAUTI. The implementation of a multidiscipli-
nary approach for prevention of VAP in ICUs in Pakistan 
[34] yielded a reduction from 18 to 13% in the VAP rate, 
and in India [22] VAP incidence decreased from 17.4 
to 10.8 per 1000 ventilation days. In 16 ICUs in India a 
similar intervention strategy for CLABSI also showed a 
reduction in CLABSI incidence rates from 6.4 to 3.9 per 
1000 central line days [21].
Finally, Navoa-Ng et  al. in the Philippines targeted 
CAUTI and reported a reduction of CAUTI from 11.0 
to 2.66 per 1000 urinary catheter days as a consequence 
of applying an infection prevention bundle together with 
education, monitoring and feedback [56].
Additional information
Sixty-three papers were published in journals listed as 
Q3 or Q4 by the Web of Sciences but only nine [64–72] 
of those met our inclusion criteria after full text review. 
Those nine papers described six independent studies, all 
emanating from the countries already included in our pri-
mary analysis. The data extracted from those publications 
did not add novel information nor significantly changed 
the findings from our review of the information pre-
sented in our primary analysis. Specifically, the infection 
rates in these nine studies all fell within the range found 
in our primary analysis. In addition, only one paper from 
India [64] presented resistance rates of ESKAPE organ-
isms; these rates all fell within the categories specified for 
India in Table 3. However, this paper also had resistance 
rates for E. coli against aminoglycosides, fluoroquinolo-
nes, and  3rd generation cephalosporins, all were > 50%. Of 
note, Ikeh et  al. reported [73] MRSA contamination of 
instruments and surfaces in an Nigerian ICU, and Joseph 
et al. [69] found evidence that some strains of P. aerugi-
nosa and A. baumannii were shared between the ICU 
environment and patients, and one of 16 HCWs carried 
a P. aeruginosa strain that was shared with a patient that 
had developed VAP.
Discussion
In this systematic scoping review, we have shown that 
endemic nosocomial infections represent a major burden 
and safety issue for patients admitted to intensive care 
in lower-middle income countries. Unfortunately, there 
were relatively few studies on this topic published from 
LMICs in a highly ranked scientific journals (Q1/Q2 by 
Web of Science). From 50 LMICs, we only identified 51 
qualified published studies performed in 11 LMICs over 
a thirteen-year time frame. Supplementing information 
from studies published in Q3/Q4 journals was not help-
ful since only nine additional papers published in these 
journals met our inclusion criteria, and they did not 
expand the areas already covered. There is, thus, a great 
unmet need in most LMICs to perform surveillance of 
ICU-acquired infections and to characterize the nosoco-
mial pathogens involved. Such data are needed in order 
to obtain a more comprehensive view and monitor the 
problems of LMICs to control ICU-acquired infection 
and combat resistance to antimicrobial agents in their 
settings.
The ICU-acquired infection rates were quite high in 
LMICs, with an average point prevalence rate of 22.4 
infected patients per 100 present in the ICU. This rate 
is comparable, albeit somewhat higher, to the aver-
age point prevalence rate of 19.5% recorded in ICUs 
across West-European countries in the same time 
frame (2011–2012) [4]. The device-associated infection 
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indices were also comparable to those recorded in West-
European ICUs at that time, 9.5 VAP/1000 intubation 
days, 3.3 CLABSI/1000  days with central line and 4.5 
CAUTI/1000  days with urinary catheter [10]. Thus, the 
overall impression is that ICU-acquired infections in 
LMICs are quite similar in their nature, but that rates are 
somewhat higher (approximately 15%) in LMIC ICUs 
compared to ICUs in West-European countries.
ICU length of stay and ICU mortality are important 
outcomes of intensive care. In studies retrieved by our 
search, the overall length of stay was 10—11 days and the 
overall ICU mortality rate was 33.6% (varying from 14 to 
70% across the studies). In the same time frame in Euro-
pean countries, based on ICU surveillance from 2008 
to 2012, the median (IQR) length of stay was 10 (8–12) 
days, which was highly comparable to the length of stay 
in LMICs [10]. However, mortality rates differed signifi-
cantly. On average, 15.3% of EU patients staying more 
than two days died in the ICU, ranging from 8.7% in Lux-
embourg to 18.1% in France [10]. The Extended Preva-
lence of Infection in Intensive Care (EPIC II) study (2007) 
involving 1265 ICUs and 75 countries found an over-
all ICU mortality rate of 18.2% (2370/13,011 patients). 
Infected patients had higher ICU mortality rates (25.3%) 
and longer ICU lengths of stay (16  days [IQR, 7–34]) 
[9, 10]. Thus, the overall ICU mortality rate of 33.6% 
retrieved in this scoping review was much higher in 
LMICs, indicating that, compared to high income coun-
tries, patients in ICUs in LMICs die at a higher rate and 
that death comes relatively early during their ICU stay. 
The fact that in LMICs the mean age of ICU patients was 
much lower than in high income countries (50 years ver-
sus 60 years, respectively) further underscores the major 
discrepancy in ICU survival between these two groups of 
countries.
Gram-negative bacteria were responsible for more 
than 50% of the total number of ICU-acquired infections 
recorded in LMICs. This species distribution contrasts 
with findings from studies done in West-Europe at that 
time where the prevalent cause of healthcare-associated 
infections had switched over to Gram-positive micro-
organisms (72.7%) (EPIC II study) [9]. The microorgan-
isms most frequently isolated from ICU infections in a 
later study [4] were in decreasing order, E. coli (15.9%), 
S. aureus (12.3%), Enterococcus spp. (9.6%), P. aeruginosa 
(8.9%), Klebsiella spp. (8.7%), coagulase-negative staphy-
lococci (7.5%), Candida spp. (6.1%), Clostridium difficile 
(5.4%), Enterobacter spp. (4.2%), Proteus spp. (3.8%) and 
Acinetobacter spp. (3.6%) [4]. Especially the proportion of 
infections caused by Acinetobacter spp. in ICUs in LMICs 
was more than six times higher compared to West-Euro-
pean countries (24% versus 3.6%) [9].
The ESKAPE group of pathogens will be of increasing 
relevance to antimicrobial chemotherapy in the com-
ing years. Our findings revealed a high rate of multid-
rug-resistant (MDR) Gram-negative bacilli causing ICU 
infections in LMICs. The high proportions of strains 
resistant to third generation cephalosporins and of mul-
tidrug resistance among Gram-negative bacteria are 
especially worrisome. Comparably high rates of MDR 
among Gram-negative bacilli isolated from patients with 
invasive infections have been reported from Italy, Greece 
and some in France (EARS-Net by 30 EU/EEA countries 
in 2014) [11]. In contrast, much lower MDR rates among 
Gram-negative bacilli were observed from invasive infec-
tions in Sweden and the Netherlands [11]. The high per-
centages of resistance to carbapenems of P. aeruginosa, 
A. baumannii and K. pneumoniae isolates found in this 
scoping review reflect the challenges of treatment of ICU 
patients in LMICs. Although not reported in the studies 
included in this review the determinants of antimicrobial 
resistance in LMICs are likely to include a high selection 
pressure due to overconsumption of antibiotics and the 
lack of barriers against the spread of selected resistant 
clones in healthcare settings.
The implementation of a multidisciplinary approach 
for prevention of HAIs in ICUs from LMICs showed that 
reductions in the HAI rate are possible in LMICs. Some 
studies reported effective interventions including contact 
precautions, active surveillance cultures, monitoring, 
audit and feedback of preventive measures, patient isola-
tion or cohorting, HH improvement programs, and envi-
ronmental cleaning. This is also highlighted by the recent 
evidence-based WHO Guidelines on the core compo-
nents of IPC programs, which strongly recommend mul-
timodal strategies to translate IPC measures into clinical 
practice [63].
One of the most comprehensive guidelines is the 2013 
European Society of Clinical Microbiology and Infec-
tious Diseases (ESCMID) Guidelines for the management 
of infection control measures to reduce transmission of 
multidrug-resistant (MDR) Gram-negative bacteria [74]. 
In endemic settings, HH and contact precautions were 
the only two interventions that were strongly recom-
mended for all three pathogens (MDR-K. pneumoniae, 
MDR-P. aeruginosa, and MDR-A. baumannii) in addi-
tion to isolation for MDR-K. pneumoniae and isolation, 
alert codes, education, and environmental cleaning for 
MDR-A. baumannii. In epidemic settings, hand hygiene, 
contact precautions, active screening, isolation and, last 
but not least, environmental cleaning are strongly rec-
ommended for all three pathogens in addition to alert 
codes and cohorting for MDR-K. pneumoniae [74]. Inter-
estingly, implementation of HH best practices and envi-
ronmental cleaning was reported in only few studies in 
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LMICs so far. Effective HH compliance is widely recog-
nized and strongly recommended by WHO to reduce 
transmission of pathogenic microorganisms in health-
care. Likewise, the important role of the innate envi-
ronment of the ICU providing sources and routes of 
transmission of MDR microorganisms is gaining rec-
ognition worldwide. This scoping review revealed that 
implementation of these guidelines is essentially possi-
ble in LMICs, and are sorely needed to reduce the high 
burden of disease caused by ICU-acquired infections in 
these settings. Much room for further high quality obser-
vational and interventional research remains that should 
include more countries with a LMIC status, and target 
novel interventions that are cost-effective in this particu-
lar setting.
The ICU cannot be rendered sterile but every effort 
should be made to reduce the number of ICU-acquired 
healthcare-associated infections (HAI) and the risk of 
spread of resistant nosocomial pathogens. Strategies to 
minimize infection have been incorporated into various 
guidelines on ICU design that are available in the UK, 
the USA and Europe [75, 76]. An ICU should accom-
modate at least 6 beds with 8–12 beds considered as the 
optimum. Hospitals with several smaller units should 
be encouraged to rearrange these units into a single 
larger department to improve efficiency. A larger ICU 
may provide opportunities to create separate, special-
ized functional subunits with 6–8 beds, sharing the same 
geographical, administrative, and other facilities [75, 76]. 
However, of those included in this review most ICUs in 
LMICs still had open ward designs with one large room, 
with beds separated by curtains only, if at all, they did not 
have separate cubicles or separate isolation rooms. The 
numbers of beds ranged between 4 and 75 beds. These 
open ICU designs are not optimal, they compare unfa-
vorably with the current trend to construct ICUs as a 
series of separate rooms to better protect patients against 
ICU-acquired infections [75]. Thus, the roles of the envi-
ronment and of HCWs in the endemicity and transmis-
sion of nosocomial pathogens in ICU settings should be 
further studied and delineated, they should no longer be 
underestimated. Also, not all ICUs in LMICs had dedi-
cated and qualified intensivists; however, most of them 
did have multidisciplinary teams in charge of the patients 
(data not presented).
A limitation of this review is posed by the relatively low 
number of qualified studies that were performed in only 
a minority of the 50 countries belonging to the group of 
LMICs. We also restricted our review to publications in 
the English language. Although the vast majority of med-
ical and healthcare research is published in English, we 
may have missed important information from research-
ers that elected to publish their data in another language. 
Thus, this review cannot be taken to reflect the full scope 
of ICU-acquired infections in all LMICs, but from our 
perspective this currently represents the best available 
view on infections acquired in ICUs and the species and 
resistance profiles of the organisms causing such infec-
tions in LMICs.
Conclusions
Our systematic scoping review describes the current evi-
dence of ICU-acquired infections in LMICs. Many gaps 
in knowledge remain since most LMICs have not pro-
duced high quality reports. However, from the reported 
evidence it is clear that the rate of ICU-acquired infec-
tions is likely to be somewhat higher in LMICs compared 
to high income countries and that the ICU mortality 
rate is much higher. MDR Gram-negative bacilli, espe-
cially Acinetobacter spp. and Pseudomonas spp. from the 
environment clearly play a much more dominant role in 
LMICs than in high income countries. However, inter-
ventions to improve this situation have been shown to be 
feasible and effective, even cost-effective.
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